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Without [industry
support], our abil-
ity to improve the
quality of medical
care would be cur-
tailed considerably,
and, unfortunately,
I do not see state
and federal govern-
ments or insurance
companies stepping
up to be likely
sources for this
funding.he American College of Cardiology (ACC) leaders recently initiated a meeting with
representatives from the U.S. Office of the Inspector General (OIG) and the U.S.
Department of Justice (DOJ) to discuss how we address conflicts of interest and
elationships with industry and funding for the College’s educational meetings and other
ctivities. Many of you are probably aware that industry supports a broad array of College
ctivities including professional education, quality programs, the Annual Scientific Session
xpo, and digital products through educational and other types of grants. This support,
hich constitutes about 38% of the College’s revenues, enables the College to provide pro-
rams that we would otherwise not be able to offer. In addition, without this support, the
egistration fees for the Annual Scientific Session and i2 Summit would have to be more
han double their present amount, and member dues would have to increase significantly.
We discussed with the OIG and DOJ representatives that the College’s science and
ducation has been and will remain objective, independent, and evidence-based despite
ndustry support because of the College’s long-established and solid “firewalls” between
ontent development and such external support. With all such activities, the College
dheres to our own strict internal policies and procedures to manage conflicts of interest
nd relationships with industry, as well as follows guidelines established by the American
ouncil for Graduate Medical Education (ACGME).
These unrestricted educational grants from industry to support medical education and
arts of our quality initiatives are important to the College. Without them, our ability to
mprove the quality of medical care would be curtailed considerably, and, unfortunately,
do not see state and federal governments or insurance companies stepping up to be
ikely sources for this funding. As it is, the ACC estimates that our members actually
ay 80% to 90% of their continuing medical education costs out of pocket.
hanging Relationships
hether it is due to pressure from external or internal forces, we are seeing changes in
he relationships between industry and medical providers. Pfizer has decided that it will
o longer offer educational grants to for-profit meeting organizers, for example, com-
ercial medical education companies. Other pharmaceutical companies will most likely
ollow. The Association of American Medical Colleges (AAMC) has suggested to medi-
al schools that pharma-sponsored gifts, lunches, and educational sessions should also
ease. The American Medical Association announced several months ago that anyone
ho had received $10,000 or more from industry in his or her lifetime could no longer
e a representative on the Relative Value Scale Update Committee.
In recent months, I have met with several congressional members to impress upon them
he value of using our guidelines, performance measures, and appropriate use criteria to im-
rove the value of care provided to patients. Some members commented that the documents
are written by persons with industry conflicts, so we need a less conflicted body to produce
uch documents.” Massachusetts has enacted legislation requiring public disclosure of gifts
rom a pharmaceutical or medical device manufacturing company valued at $50 or more.
T
b
f
A
f
o
e
f
A
W
s
m
i
b
r
S
a
c
t
r
•
•
•
v
o
t
c
c
l
s
m
p
k
c
p
t
a
•
•
•
r
v
a
p
t
o
T
i
p
t
m
i
i
t
a
f
O
v
e
o
h
p
a
a
d
o
i
d
r
h
“
r
k
A
t
w
t
w
c
b
A
W
A
2
1275JACC Vol. 52, No. 15, 2008 Weaver
October 7, 2008:1274–5 President’s Pagehe federally-proposed Sunshine Act for public disclosure has
een endorsed by the Pharmaceutical Research and Manu-
acturers of America and the Advanced Medical Technology
ssociation, as well as the ACC.
Clearly, the topic of industry relationships has been
ront and center, and the momentum is in the direction
f tighter restrictions. Where all of this will end—and
ven more important, what the alternative business model
or funding professional education will be—is not clear.
dvice for Avoiding Pitfalls
hat do you need to be cautious about in your relation-
hip with industry or other possible conflicts? Since the
eeting, I have tried to educate myself more about what
s on the radar screen of these governmental oversight
odies, how a person could get into trouble, and which
elationships may be problematic.
All of you are likely aware of the Federal Anti-Kickback
tatute that prohibits offering, paying, soliciting, or receiving
nything of value to induce or reward referrals of federal health
are program business. Obvious examples might be a kickback
o members of a formulary committee or a reward to induce
eferrals. Some of the questions investigators ask include:
Does the arrangement have the potential to affect clini-
cal decision-making?
Does the arrangement have the potential for overuse or
misuse?
Are the consequences of an arrangement likely to lead
to increased costs for federally funded programs?
The investigators are trying to determine if anything of
alue is being exchanged between the parties or if some-
ne is paying for the referrals.
Grants for education and research are legitimate as long as
here is no control over the content or the speaker. Physi-
ians may be paid for consulting; however, if their fee ex-
eeds fair market value or the consultants are merely passive
isteners while “consulting,” the relationship comes under
uspicion. Compensation for “research” provided by sales and
arketing divisions of a company and set up to market a
roduct is a no-no. A fellowship stipend in return for mar-
et share of a product would also not pass muster.
Joint ventures, such as those with a hospital, ambulatory care
enter, or imaging center, can also be an unsuspecting trap for
hysicians. Are the physicians selected and retained in a manner
hat takes into account the value or volume of referrals? Other
rrangements that raise a red flag include those in which:
Participants are expected to make a large number of refer-
rals to the venture and are offered a greater or more fa-
vorable business or investment opportunity for doing so.
Participants are encouraged to make referrals or the
venture tracks its sources of referrals and distributes
this information to participants. WParticipants are permitted to borrow their capital in-
vestment from the venture or from another participant
and pay back the loan from profit distributions.
All are red flags that the venture is a vehicle to disguise
eferrals, and the OIG is aware of a proliferation of joint
enture arrangements. Other examples might include di-
gnostic laboratory services, durable medical equipment
roviders, or an arrangement in which you receive some-
hing for free or far below the purchase value, such as
ffice space, accounting services, and clerical support.
hese ventures are set up not to merely raise capital but
nstead to lock up a stream of referrals and to compensate
articipants indirectly by sharing in profits of the venture.
Why do hospitals and others provide economic incentives
o physicians? Many of these ventures are in competitive
arkets, and they are attempting to recruit physicians and
ncrease patient referrals. Some physicians even solicit these
ncentives. In exchange, the physician is expected to bring
he majority of his or her patients to the venture.
Enforcers and oversight bodies also look for recruitment
rrangements promising income guarantees, interest-
ree loans, or turnkey setups—just bring your patients.
ther suspicious activities might include payment for ser-
ices that require few substantive duties, payment that far
xceeds fair market value for the service, or investment
pportunities that guarantee returns. If you wonder “why
ave they come to me” or it seems too good to be true, it
robably is. Any of these things should cause you to stop
nd get professional advice before signing.
Drug prescriptions can also be a problem if the program is
imed at switching drugs within a class in return for either
irect or indirect compensation, such as frequent flyer miles
r a “research grant” in which physicians are paid for provid-
ng minimal record-keeping tasks related to a patient’s con-
ition or possible need for treatment, or for inappropriate
ecommendations for off-label use. All of these practices
ave resulted in criminal fraud and abuse convictions.
With all of this detail, it is important to note that there are
safe harbors” that can be constructed around some mutual ar-
angements. If you find this information of interest, let me
now, and we can delve into the topic further. That said, the
CC has clearly distinguished itself by being proactive and
ransparent on this important topic. The information posted on
ww.acc.org about support from external sources demonstrates
he seriousness of our commitment to transparency. Our fire-
alls, strict insistence and scrutiny of disclosures, and our
ommitment to patient-centered and scientific evidence-
ased medicine are the College’s tradition and its future.
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